Novartis AG Common Stock (NY:NVS)

141.00 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

59 60 Next >

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 31, 2024

U.S. stock futures were mostly lower this morning, with the Nasdaq futures falling more than 200 points on Wednesday.

Via Benzinga

3 Hidden Healthcare Stocks Poised for a Breakout This Year ↗

January 30, 2024

As the market preferences start to switch toward stable and defensive names like healthcare, these stocks could help your portfolio.

Via InvestorPlace

Earnings Outlook For Novartis ↗

January 30, 2024

Via Benzinga

(NVS) - Analyzing Novartis's Short Interest ↗

January 05, 2024

Via Benzinga

Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning

January 05, 2024

Via Investor Brand Network

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Big Players' Recent Trades in NVS Options ↗

January 04, 2024

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow ↗

January 24, 2024

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' ↗

January 24, 2024

FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.

Via Benzinga

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst ↗

January 12, 2024

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...

Via Benzinga

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition ↗

January 11, 2024

Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the

Via Benzinga

Bullish Continuation In '24? 3 Market Areas To Watch ↗

January 10, 2024

This article discusses 3 market areas that should outperform dramatically over the next 12 months...

Via Talk Markets

What's Been Happening With Cytokinetics Stock? ↗

January 09, 2024

Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength.

Via Benzinga

Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? ↗

January 08, 2024

Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS).

Via Benzinga

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal ↗

January 08, 2024

The company is working on a treatment for a disease that can lead to heart failure.

Via Investor's Business Daily

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗

January 08, 2024

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an

Via Benzinga

Insufficient self-sufficiency of raw materials in Japan

January 08, 2024

Via AB Newswire

Topics Supply Chain

Voyager Therapeutics stock pops 30% on deal with Novartis

January 08, 2024

Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took

Via MarketBeat

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value ↗

January 08, 2024

The year's biggest medical conference kicked off with a melee of buyout news.

Via Investor's Business Daily

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery ↗

January 08, 2024

Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part

Via Benzinga

Topics Artificial Intelligence

Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis ↗

January 07, 2024

Isomorphic Labs will get upfront cash and milestone payments.

Via Investor's Business Daily

Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗

January 07, 2024

Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...

Via Talk Markets

Voyager Therapeutics Stock Tanked After-Hours - Here's Why ↗

January 04, 2024

Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering

Via Benzinga

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗

January 02, 2024

VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.

Via InvestorPlace

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.